Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $1,619,174.70 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 54,153 shares of Hims & Hers Health stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the sale, the insider now directly owns 165,650 shares of the company’s stock, valued at approximately $4,952,935. This trade represents a 24.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.16, for a total value of $54,171.24.

Hims & Hers Health Stock Down 0.0 %

Shares of Hims & Hers Health stock opened at $30.89 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $35.02. The business’s fifty day moving average is $28.22 and its two-hundred day moving average is $22.18. The firm has a market cap of $6.75 billion, a PE ratio of 70.20 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the business posted ($0.04) earnings per share. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Trading of Hims & Hers Health

Institutional investors have recently modified their holdings of the company. Quest Partners LLC raised its holdings in Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares during the period. Stonekeep Investments LLC increased its position in shares of Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after acquiring an additional 882 shares in the last quarter. CWM LLC raised its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares during the period. Cadent Capital Advisors LLC lifted its holdings in shares of Hims & Hers Health by 1.5% during the 4th quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock valued at $1,745,000 after acquiring an additional 1,060 shares in the last quarter. Finally, Raleigh Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on HIMS shares. Piper Sandler raised their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Needham & Company LLC raised their price target on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Morgan Stanley assumed coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective for the company. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Finally, Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.